Trevi Therapeutics, Inc. TRVI · Stock Open Trevi Therapeutics, Inc. in new tab
Trevi Therapeutics, Inc. Analysis (TRVI)
Is Trevi Therapeutics, Inc. a good investment? Trevi Therapeutics, Inc. (TRVI) is currently trading at 14.89 USD. Market analysts have a consensus price target of 28.18 USD. This suggests a potential upside from current levels.
Earnings Schedule: Trevi Therapeutics, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.58.
Investor FAQ
Does Trevi Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.35.
Company Profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Community Discussion